BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	124.4	217.9	219.02	330.51	163.64	136.32
Short-Term Investments	700	300	400	393.76	329.76	552.96
Cash & Short-Term Investments	824.4	517.9	619.02	724.27	493.4	689.28
Cash Growth	55.19%	-16.34%	-14.53%	46.79%	-28.42%	34.36%
Accounts Receivable	65.79	58.96	47.36	26.69	11.27	5.05
Other Receivables	6.2	32.18	33.37	30.67	28.25	23.61
Receivables	72	91.14	80.72	57.36	39.52	28.66
Inventory	29.25	20.52	15.96	16.55	4.9	9.03
Prepaid Expenses	31.25	6.87	2	3	4.07	7.57
Total Current Assets	956.89	636.43	717.7	801.18	541.89	734.54
Property, Plant & Equipment	37.7	43.11	49.57	56.2	34.01	8.89
Long-Term Investments	6.65	7.65	8.33	20.34	10	-
Goodwill	-	17.09	17.09	17.09	17.09	17.09
Other Intangible Assets	116.59	73.26	114.07	151.04	210.95	261.92
Other Long-Term Assets	37.56	37.85	5.94	4.64	7.89	1.42
Total Assets	1,155	815.38	912.7	1,050	821.82	1,024

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.91	2.09	4.22	2.16	2.08	0.49
Accrued Expenses	-	27.03	22.29	16.57	17.22	14.39
Current Portion of Leases	3.83	3.73	3.59	3.65	3.49	3.94
Other Current Liabilities	78.94	3.31	3.13	23.87	9.07	6.3
Total Current Liabilities	84.69	36.16	33.23	46.25	31.86	25.13
Long-Term Leases	-	2.85	5.84	9.44	12.28	0.48
Long-Term Unearned Revenue	-	-	-	2.5	2.5	2.5
Long-Term Deferred Tax Liabilities	12.43	18.73	27.13	35.52	43.92	52.31
Total Liabilities	97.12	57.74	66.19	93.71	90.56	80.42

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,343	1,244	1,243	1,231	1,031	1,031
Additional Paid-In Capital	264.91	-	-	-	-	212.85
Retained Earnings	-544.89	-482.93	-398.32	-281.85	-325.52	-353.91
Comprehensive Income & Other	-15.74	-18.54	-26.58	-7.96	-2.38	-2.16
Total Common Equity	1,047	742.09	817.67	940.96	702.86	887.54
Minority Interest	10.83	15.55	28.84	15.81	28.4	55.91
Shareholders' Equity	1,058	757.64	846.51	956.77	731.27	943.45
Total Liabilities & Equity	1,155	815.38	912.7	1,050	821.82	1,024

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	3.83	6.58	9.43	13.09	15.77	4.42
Net Cash (Debt)	820.56	511.33	609.59	711.18	477.64	684.86
Net Cash Growth	56.43%	-16.12%	-14.28%	48.90%	-30.26%	33.49%
Net Cash Per Share	6.47	4.15	4.95	5.91	4.63	6.76
Filing Date Shares Outstanding	130.91	124.36	124.26	123.08	103.08	103.08
Total Common Shares Outstanding	130.91	124.36	124.26	123.08	103.08	103.08
Working Capital	872.21	600.27	684.47	754.93	510.03	709.42
Book Value Per Share	8.00	5.97	6.58	7.65	6.82	8.61
Tangible Book Value	930.85	651.75	686.51	772.83	474.82	608.52
Tangible Book Value Per Share	7.11	5.24	5.52	6.28	4.61	5.90
Machinery	-	33.26	31.6	31.19	24.66	24.55
Construction In Progress	-	-	-	37.57	14.91	-
Leasehold Improvements	-	38.15	38.15	0.34	0.34	0.34

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 15, 2026

Data Sources Report a data error